S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
NASDAQ:CLSD

Clearside Biomedical (CLSD) Stock Price, News & Analysis

$1.39
-0.01 (-0.71%)
(As of 03/1/2024 ET)
Today's Range
$1.35
$1.43
50-Day Range
$1.04
$1.48
52-Week Range
$0.65
$1.54
Volume
76,875 shs
Average Volume
141,035 shs
Market Capitalization
$88.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Clearside Biomedical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
259.7% Upside
$5.00 Price Target
Short Interest
Healthy
0.25% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.87mentions of Clearside Biomedical in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$599,999 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.55) to ($0.59) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.94 out of 5 stars

Medical Sector

402nd out of 950 stocks

Pharmaceutical Preparations Industry

189th out of 440 stocks


CLSD stock logo

About Clearside Biomedical Stock (NASDAQ:CLSD)

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

CLSD Stock Price History

CLSD Stock News Headlines

Clearside Biomedical, Inc. (CLSD)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
CLSD Apr 2024 5.000 call
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Clearside Biomedical: Q3 Earnings Insights
See More Headlines
Receive CLSD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
3/03/2024
Next Earnings (Confirmed)
3/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CLSD
Employees
36
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$6.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+259.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-32,950,000.00
Net Margins
-1,687.74%
Pretax Margin
-1,687.74%

Debt

Sales & Book Value

Annual Sales
$1.33 million
Book Value
$0.18 per share

Miscellaneous

Free Float
57,376,000
Market Cap
$88.42 million
Optionable
Optionable
Beta
2.28
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. George M. Lasezkay J.D. (Age 72)
    Pharm.D., Pharma.D., President, CEO & Director
    Comp: $816.4k
  • Mr. Charles A. DeignanMr. Charles A. Deignan (Age 60)
    Chief Financial Officer
    Comp: $536.95k
  • Dr. Thomas A. Ciulla M.B.A. (Age 59)
    M.D., Chief Medical Advisor-Retina
    Comp: $597.21k
  • Ms. Jenny R. Kobin (Age 57)
    Head of Investor Relations
  • Mr. Rick McElheny
    Vice President of Corporate Development
  • Mr. Rafael V. Andino (Age 59)
    Senior Vice President of Engineering & Manufacturing
  • Ms. Susan L. Coultas Ph.D.
    Chief Clinical Officer
  • Mr. Leslie B. Zacks (Age 55)
    Secretary














CLSD Stock Analysis - Frequently Asked Questions

Should I buy or sell Clearside Biomedical stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLSD shares.
View CLSD analyst ratings
or view top-rated stocks.

What is Clearside Biomedical's stock price target for 2024?

4 brokers have issued 1-year price objectives for Clearside Biomedical's stock. Their CLSD share price targets range from $4.00 to $6.00. On average, they predict the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 259.7% from the stock's current price.
View analysts price targets for CLSD
or view top-rated stocks among Wall Street analysts.

How have CLSD shares performed in 2024?

Clearside Biomedical's stock was trading at $1.17 at the start of the year. Since then, CLSD shares have increased by 18.8% and is now trading at $1.39.
View the best growth stocks for 2024 here
.

Are investors shorting Clearside Biomedical?

Clearside Biomedical saw a decrease in short interest in February. As of February 15th, there was short interest totaling 161,900 shares, a decrease of 12.0% from the January 31st total of 183,900 shares. Based on an average daily volume of 183,800 shares, the days-to-cover ratio is presently 0.9 days.
View Clearside Biomedical's Short Interest
.

When is Clearside Biomedical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024.
View our CLSD earnings forecast
.

How can I listen to Clearside Biomedical's earnings call?

Clearside Biomedical will be holding an earnings conference call on Tuesday, March 12th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical, Inc. (NASDAQ:CLSD) issued its quarterly earnings results on Monday, November, 13th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. The company earned $0.86 million during the quarter, compared to the consensus estimate of $0.22 million. Clearside Biomedical had a negative trailing twelve-month return on equity of 533.87% and a negative net margin of 1,687.74%. During the same period in the previous year, the firm posted ($0.13) earnings per share.

What other stocks do shareholders of Clearside Biomedical own?
When did Clearside Biomedical IPO?

(CLSD) raised $50 million in an IPO on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

Who are Clearside Biomedical's major shareholders?

Clearside Biomedical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.42%), Stifel Financial Corp (0.05%), Simplex Trading LLC (0.00%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bradford T Whitmore, Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, Nancy J Hutson, Richard T Burke and Thomas Ciulla.
View institutional ownership trends
.

How do I buy shares of Clearside Biomedical?

Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLSD) was last updated on 3/3/2024 by MarketBeat.com Staff